Member Info for Parpaing

totally agree with your sentiments. The AIM MMs couldn't organize a party in a brewery. Come to think of it, the London stock Exchange is a total mish-mash of headless chickens rolling around with no aim (no pun intended) or direction. There is no rhyme or reason in the UK stock exchanges. XEN will not be the last to follow the US route to market.

Just got into molecules and his / her its life when along comes a commercial break. Now I have to wait for the next episode. it's worse than Homeland, hoping the scriptwriters don't die before the story ends....

Great research - did you send your articles to Paul Mines? I am sure it would make a great xmas pressie.

Excellent news and your patience / patients will be rewarded !

Nominee account then. Oh well, at least the BIOM BOD now has some new sales prospects. Come on Paul, go and get a curry and sell some fiber optic furnaces in India!

Well, it is certainly a coincidence that when researching V A Pereira the name sticks to a large plastics manufacturer with a T/O of more than 600 M, has US connections, on the M&A trail and expanding. BIOM is a vary nice fit. India is going for the countrywide broadband installation and how handy would BIOM be to them? Fiber optic furnace technology, a new type of bio plastics division etc. all at a knock-down price?

http://www.pr.com/press-release/525901

SINTEX INDUSTRIES LTD Address : 417 419 MIDAS SAHAR PLAZA, MATHURADAS VASANJI ROAD, NEXT TO HOTEL AIRPORT KOHINNOOR J B NAGAR, ANDHERI EAST, MUMBAI 400059 Contact Person : MR P K VED/MR V A PEREIRA Contact Nos. : +(91)-22-28208962,+(91)-22-28208520,+(91)-22-28208963

Sintex of India could also make good use of the Stanelco RF Technologies division. IMHO, BIOM having consolidated its shares and got rid of the small investors, is in a good position for an exit strategy. Of course I could be wrong, but I think that news is due very soon and Mr. Mines will be announcing that an offer is on the table, unless, of course, sales have vastly improved.

BIOM is vulnerable to a takeover considering its marcap equals cash in the bank. This means that a company like Sintex could easily buy up BIOM and move the whole company to India, complete with BIOM's patents and technology. BIOM is a perfect fit for Sintex. Paul Mines and his team have done all the hard work setting up the company and now, IMHO, an Indian company is not going to take too long to decide to buy BIOM. DYOR. see: http://tech2.in.com/tags/optic-fibre-network

India is going to need a lot of fiber optic cable. BIOM MAKES fiber optic furnaces. HerE'S WHY. In late 2010, Telecom Regulatory Authority of India (TRAI) proposed the National Broadband Plan (NBP), an ambitious project that aims to use Rs 600 billion of investment to bring high-speed connectivity to PCs in 160 million households. The plan outlines setting up of State Optic Fibre Agencies (SOFA) in each state and another National Optic Fibre Agency (NOFA). Under the NBP, the Bharat Broadband Network Limited (BBNL), a special purpose vehicle, was set up by the government. The objective of BBNL is to manage and operate the National Optic Fibre Network (NOFN). The NOFN will eventually provide connectivity to 250,000 Gram Panchayats. If realised, it has the potential to transform many aspects of India, including areas such as education, business, entertainment, environment, health households and e-governance services. Initiated under the National Telecom Policy (NTP) 2012, BBNL hopes to deliver affordable and reliable broadband on demand by 2015. The organisation has set a target of 175 million connections by 2017. By 2020, BBNL hopes to have 600 million subscribers with a minimum 2Mbps speed, up to 100Mbps on demand.

Could this be the same Mr V A Pereira from the plastics industry Sintex Industries Ltd? See: http://mumbai.citizensindia.com/plastic-product/sintex-industries-ltd/id_71927 and http://www.sintex-plastics.com/contactus/contact.htm Mr. Pereira now owns nearly 15 % of BIOM. This company is starting to get really interesting.

The last update on the Eropoxen trial was 14/102013. Reason: Study has now received ethics committee approval Updated on 14/10/2013 3:10:45 PM See: https://www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=364142&showHistory=true

well, the SP in the US is anyone's guess, a bit like asking 'How long is a piece of string?' However, the Rusnano / Pharmsyntex / Synbio /Xenetic joint plan is, I assume, to be one of the biggest pharmaceutical manufacturer in the world. As I mentioned, the Russian government has its own guys on the BOD as NEDs. The Rusnano plan is huge and includes several projects.

Did you mean Eropoxen rather than Oncohist? The up to date official trial data is here: https://www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=364142

Yes, I do know a lot about the Russians - thank you for noticing. A pilot clinical study (phase I/II) with Acute Myeloid Leukemia (AML) patients has been performed at the Saarland University Hospital at Homburg/Saar, Germany. The data showed that Oncohist™ is safe and well tolerated by patients while the first encouraging signs of clinical effect included three partial remissions, increase of thrombocytes and normalization of leukocytes as well as stabilization for several months in two patients. Oncohist™ has been granted orphan drug status for Acute Myeloid Leukemia (AML) by both the FDA and EMA and additional orphan drug status for Acute Lymphocytic Leukemia (ALL) in Europe by the EMA. therefore, no further results appear to be necessary the orphan drug status in the US AND Europe has been granted. This was published today. See: http://www.bioportfolio.com/channels/Oncohist

Mr. Roman Sergeevich Knyazev serves as Senior Investment Manager of Rusnano. Mr. Knyazev has been a Non-Executive Director at Xenetic Biosciences PLC since January 27, 2012. Mr. Knyazev serves as a Director of SynBio LLC. He has been Director of Open Joint-Stock Company Pharmsynthez since February 20, 2013. http://investing.businessweek.com/research/stocks/people/person.asp?personId=154208607&ticker=XEN:LN&previousCapId=23143993&previousTitle=XENETIC%20BIOSCIENCES%20PLC

$1.50 assumed doubling of SP on opening? We will be in the money the first day on the OTC market according to Parcae capital.

What a load of softies are whinging on this board ! You have to understand that the Russian government is driving XEN and Scott has to follow the directions by his BOD, in particular, Mr. Dmitry Genkin. Mr. Genkin, for those PIs unaware of the Russian influence, is also Chairman of Pharmsynthez, the Russian drug manufacturing facility and XEN partner. XEN or GSL is the vehicle for Pharmsynthez to market its products in the US. If you DYOR and check out http://en.pharmsynthez.com/Pharmsynthez.3.html you will see that news on MyeloXEN will be announced at the end of 2013. Rusnano, is behind Pharmsynthez and XEN. See: http://en.rusnano.com/about/subsidiary/rusnano-usa The transition to the USA is all part of the excellent plan by the Russian government to become the world leader in pharmas. I have no doubt that the nigration to the US OTC markets will be the beginning of the rise of XEN. The markets in London have had their chance with XEN and will now lose out. This is just the start of the bull run backed by the Russian Bear. DYOR.

New RNS states that the BOD has to sign a new agreement because of an error in signing without reading or taking advice. I hope the BOD takes more care of our money in future. IN ADDITION, CLAUSE 3.6.4 OF THE IRREVOCABLE UNDERTAKINGS SIGNED BY THE DIRECTORS OF XENETIC SHOULD NOT HAVE BEEN INCLUDED IN SUCH UNDERTAKINGS AND NEW UNDERTAKINGS WILL BE SIGNED WITHOUT DELAY BY EACH OF THE XENETIC DIRECTORS WITH THIS CLAUSE DELETED. THE NEW IRREVOCABLE UNDERTAKINGS WILL BE AVAILABLE FOR VIEW ON THE XENETIC WEBSITE AT www.xeneticbio.com/investorrelations IN DUE COURSE.